Dr. Michael Humeniuk Named Top Investigator in CCDR

We are proud to share that Dr. Michael Humeniuk has been recognized as the #1 investigator in Cancer Care Delivery research within the NCORP network. As of mid-August, the NCORP network included 4,222 physicians nationwide, and Dr. Humeniuk earned the top ranking for his exceptional contributions to advancing cancer care through clinical research.

NCORP Awards

The following investigators were acknowledged for their high enrollment numbers in NCI treatment and cancer control trials

Gold Award

Dr. Michael Humeniuk

Dr. Isaac Alwine

Dr. Vikas Dembla

Dr. Drew Monitto

Dr. Jeremy Kilburn

Silver Award

Dr. Steven Corso

Dr. Amy Curtis

Dr. Samuel Adediran

Research Base Meetings

Wake Forest Fall Meeting: October 6-8, 2025 - Asheville, NC

ECOG-ACRIN Fall Meeting: October 22-24, 2025- Philadelphia

Alliance Fall Meeting: November 5-7, 2025 - Chicago, IL

NRG Winter Meeting: January 22-26, 2026 - San Francisco, CA

Newly Activated Studies

These studies have recently activated.

More information can be found on CTSU.

S2427: Single Arm Phase II Study of Bladder Preservation With Immunoradiotherapy After a Clinically Meaningful Response to Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer (BRIGHT)
S2409: PRISM: PRecIsion in SCLC Via a Multicohort Study: Randomized Phase II Studies Evaluating Maintenance Durvalumab With or Without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
A232301CD: AYA Access Study: An Enhanced eHealth and Chat-Bot Enabled Delivery Model for Clinical Genetic Services in Community AYA Cancer Patients
A032302: Docetaxel Addition in Metastatic Castrate-Sensitive Prostate Cancer (ASPIRE)

Accruals, Biospecimens, & Special Entries

Underrepresented Populations

CCDR Corner

A232301CD-AYA ACCESS Study: An enhanced eHealth and Chat-bot enabled delivery model for clinical genetic services in community AYA cancer patients

Hot off the presses-another newly activated CCDR trial! This one testing remote delivery model for genetic services for our AYA patients.

Informational webinar: Thursday, October 2, 2025, at 1 PM CDT (2 PM EDT).

Follow the button below for more information on the webinar

A232301CD Webinar

Questions? Reach out to Melyssa

All About AYAs

Diving In!

Prostate Cancer Awareness Month

September is National Prostate Cancer Awareness Month, aimed to increase public awareness of the importance of prostate health and screenings, educate about risk factors and symptoms, and advocate for further research on prostate health issues.

Research has shown that prostate cancer is the most common type of cancer diagnosed in men in the United States and is the second leading cause of cancer deaths among men, especially in South Carolina, according to the Department of Health and Environmental Control (DHEC). Additionally, according to the National Cancer Institute, almost all prostate cancers are adenocarcinomas, meaning these cancer cells originate in gland cells that make and release mucus and other fluids. NCI-funded researchers continue to work towards advancing our understanding of how to prevent, detect, and treat prostate cancer due to challenges in choosing the best treatment options for patients at all stages of the disease (Wang et al., 2021).

Prostate Cancer Awareness Month is a key period for education and advocacy through events and screenings to combat stigma, promote early prevention and intervention, and minimize prostate cancer risk.

To learn more about Prostate Cancer Awareness, click the link below from the Prostate Cancer Foundation, which provides resources and toolkits for patients and the community.

Prostate Cancer Foundation